December 2007
Worldwide Biotech;Dec2007, Vol. 19 Issue 12, p5
Trade Publication
The article reports that positive, first results from a 12 month Phase IIa clinical trial with SNT-MC17 in Duchenne Muscular Dystrophy (DMD) as measured by cardiac and respiratory parameters was announced by Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on neuromuscular diseases. Gunnar Buyse, associate professor of child neurology at the University of Leuven, said that despite the small sample size of the pilot study, they saw interesting efficacy trends with SNT-MC17 that encourage further investigation of the drug in DMD.


Related Articles

  • Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). Nakamura, Harumasa; Kimura, En; Mori-Yoshimura, Madoka; Komaki, Hirofumi; Matsuda, Yu; Goto, Kanako; Hayashi, Yukiko K.; Nishino, Ichizo; Takeda, Shin'ichi; Kawai, Mitsuru // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, Special section p1 

    Background: Currently, clinical trials for new therapeutic strategies are being planned for Duchenne and Becker muscular dystrophies (DMD/BMD). However, it is difficult to obtain adequate numbers of patients in clinical trials. As solutions to these problems, patient registries are an important...

  • Santhera, Takeda Extend Pact For Idebenone In DMD. Sheridan, Cormac // BioWorld International;8/8/2007, Vol. 12 Issue 32, p1 

    This article reports on the acquisition of licensed European rights to idebenone in Duchenne muscular dystrophy (DMD) by Takeda Pharmaceutical Co. Ltd. from Santhera Pharmaceuticals AG. This deal is an extension of an existing pact between the two companies. The rights are given to Takeda in...

  • Targeting RNA to treat neuromuscular disease. Muntoni, Francesco; Wood, Matthew J. A. // Nature Reviews Drug Discovery;Aug2011, Vol. 10 Issue 8, p621 

    The development of effective therapies for neuromuscular disorders such as Duchenne muscular dystrophy (DMD) is hampered by considerable challenges: skeletal muscle is the most abundant tissue in the body, and many neuromuscular disorders are multisystemic conditions. However, despite these...

  • Randomised controlled trial of non-invasive ventilation (N IV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. Ward, S.; Chatwin, M.; Heather, S.; Simonds, A. K. // Thorax;Dec2005, Vol. 60 Issue 12, p1019 

    Background: Long term non-invasive ventilation (NIV) reduces morbidity and mortality in patients with neuromuscular and chest wall disease with hypercapnia ventilatory failure, but preventive use has not produced benefit in normocapnic patients with Duchenne muscular dystrophy. Individuals with...

  • Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. Fischmann, Arne; Hafner, Patricia; Gloor, Monika; Schmid, Maurice; Klein, Andrea; Pohlman, Urs; Waltz, Tanja; Gonzalez, Rocio; Haas, Tanja; Bieri, Oliver; Fischer, Dirk // Journal of Neurology;Apr2013, Vol. 260 Issue 4, p969 

    The purpose of this ethics approved trial was to correlate quantitative MRI with functional abilities in both ambulant and non-ambulant Duchenne muscular dystrophy (DMD). Twenty patients with genetically confirmed DMD were recruited. Physical assessment was performed using the motor function...

  • Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Govoni, Alessandra; Magri, Francesca; Brajkovic, Simona; Zanetta, Chiara; Faravelli, Irene; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P. // Cellular & Molecular Life Sciences;Dec2013, Vol. 70 Issue 23, p4585 

    Muscular dystrophy is a heterogeneous group of genetic disorders characterised by progressive muscle tissue degeneration. No effective treatment has been discovered for these diseases. Preclinical and clinical studies aimed at the development of new therapeutic approaches have been carried out,...

  • L-CARNITINE SUPPLEMENTATION IN DUCHENNE MUSCULAR DYSTROPHY STEROIDNAÏVE PATIENTS: A PILOT STUDY. Escobar-Cedillo, Rosa E.; Tintos-Hernández, Jesús A.; Martínez-Castro, Guadalupe; de Oca-Sánchez, Beatriz Montes; Rodríguez-Jurado, Rodolfo; Miranda-Duarte, Antonio; Lona-Pimentel, Socorro; Gómez-Díaz, Benjamín; Coral-Vázquez, Ramón M.; García, Silvia; López-Hernández, Luz B. // Current Topics in Nutraceutical Research;Aug2013, Vol. 11 Issue 3, p97 

    Duchenne muscular dystrophy (DMD) is a genetic neuromuscular disorder characterized by progressive weakness leading to disability. Steroid administration and physiotherapy are the most useful medical interventions in ambulant patients; In DMD, muscles present a significant deficiency of...

  • Current and emerging treatment strategies for Duchenne muscular dystrophy. Mah, Jean K. // Neuropsychiatric Disease & Treatment;Jul2016, Vol. 12, p1795 

    Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications. The...

  • Lack of Functional Benefit with Glutamine versus Placebo in Duchenne Muscular Dystrophy: A Randomized Crossover Trial. Mok, Elise; Letellier, Guy; Cuisset, Jean-Marie; Denjean, André; Gottrand, Frédéric; Alberti, Corinne; Hankard, Régis // PLoS ONE;2009, Vol. 4 Issue 5, p1 

    Background: Oral glutamine decreases whole body protein breakdown in Duchenne muscular dystrophy (DMD). We evaluated the functional benefit of 4 months oral glutamine in DMD. Methodology/Principal Findings: 30 ambulant DMD boys were included in this double-blind, randomized crossover trial with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics